Its new strategic roadmap aims to catapult the company forward.AstraZeneca (AZN -2.44%) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global biopharma sector, and its investors could potentially be wealthier too.But that doesn't make it the right choice for everyone, so it's important to dive into the details of exactly what it's setting out to do. Let's start by putting this plan into cont ...